1,721,283 research outputs found
Lo studio COMPLETE e il futuro della rivascolarizzazione dei pazienti con infarto miocardico con sopraslivellamento del tratto ST e malattia coronarica multivasale [The COMPLETE trial and the future of revascularization in patients with ST-elevation myocardial infarction and multivessel disease]
No full textLa recente presentazione e pubblicazione dello studio COMPLETE (Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI) permette di aggiungere un importante tassello al trattamento ottimale dei pazienti con infarto miocardico acuto con sopraslivellamento del tratto ST (STEMI) e malattia multivasale1. Se trattare o meno con rivascolarizzazione percutanea (PCI) e impianto di stent le lesioni non responsabili dell’infarto (non culprit) riscontrate occasionalmente durante la procedura di PCI primaria è un dilemma che molteplici studi hanno cercato di affrontare2-12. Anche in un precedente numero del Giornale Italiano di Cardiologia l’argomento era stato affrontato e discusso13
2019 CORONAVIRUS: What are the implications for cardiology?
No full textIt is the third time, in recent decades, that a zoonotic coronavirus has crossed species to infect human beings. Seventeen years ago, an outbreak of a virus whose RNA sequences closely resemble those of a virus that silently circulates in bats – the so-called “SARS-CoV” – caused severe acute respiratory syndrome with a fatality rate of 9 to 11%. A few years later (2012), the Middle East respiratory syndrome coronavirus – the so-called “MERS-CoV” – had a fatality rate of 34%. For both viruses, age and coexisting conditions such as diabetes or heart disease were independent predictors of adverse outcome
Commentary: What is the relationship between Covid-19 and cardiovascular disease?
No full textCommentary: What is the relationship between Covid-19 and cardiovascular disease
The late Holocene history of cypress (Cupressus sempervirens L.) in the Italian peninsula: New perspectives from archaeobotanical data
No full textThe objective of this research is to reconstruct the recent Holocene history of Cupressus sempervirens from the Bronze to the Roman Age in Italy. Our work consisted both in a review of published data and in the identification of novel archaeobotanical remains stored in the deposits of the National Archaeological Museum of Naples and of the Archaeological Park of Pompeii. The literature permitted to collect information linked to different plant remain typologies of the Italian cypress; 362 botanical remains were counted, of which 292 were from the Vesuvian area and 70 from other archaeological sites of the central and western Mediterranean. Data chronology spans from the second century BC to the AD fifth century for the archaeological area of ancient Campania and from the 14th century BC to the AD fourth century for the sites located in different regions. It is clear that the ‘cypress culture’ is confirmed by the archaeobotanical data found in the Roman world. Romans especially appreciated its timber but cypress was also used for many other purposes. Furthermore, the employment of timber for wells was documented in pre-Roman sites and the presence of fruits/seeds in central Italy confirms its importance also in the Bronze Age
The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism – Still a challenging issue
No full textAs about 50 % of patients with unprovoked venous thromboembolism (VTE) will develop new episodes after discontinuing therapy, indefinite treatment is suggested in patients with low or moderate bleeding risk. Baseline and post-baseline factors can help clinicians to identify patients at high risk of recurrence, who require extended treatment. Residual vein obstruction and D-dimer assay have been shown to be suitable methods for assessing the risk of VTE recurrences after a first unprovoked VTE. In treatment for VTE the use of direct oral anticoagulants (DOAC) is growing instead of the standard adjusted dose of vitamin K antagonists. The DOAC safety profile has recently been strengthened with systematic reviews and meta-analyses. Idarucizumab is only approved for the reversal of dabigatran etexilate; intravenous antidotes for factor Xa inhibitors are under development. Their advent is of great interest. In the extended treatment of VTE sulodexide has been demonstrated to significantly decrease the risk of recurrences with an excellent safety profile. Aspirin is substantially less effective than oral anticoagulants in preventing recurrences but could play a role among patients who decided to stop anticoagulants. In conclusion, for the secondary prevention of VTE several options are available, without a recognised best choice regarding the treatment duration and the choice of drugs. An individual strategy taking into account risk of recurrence, bleeding risk, therapeutic options, and patient preferences is appropriate
- …
